




GYRE Therapeutics INC
Rank 192 of 295

CATALYST
BIOSCIENCES



The relative strengths and weaknesses of GYRE Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GYRE Therapeutics INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 89% points. The greatest weakness of GYRE Therapeutics INC is the variable Liabilities, Current, reducing the Economic Capital Ratio by 120% points.

The company's Economic Capital Ratio, given in the ranking table, is 230%, being 33% points below the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	68,698
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	37,756
Liabilities, Non-Current	0
Other Assets	125
Other Compr. Net Income	1.0
Other Expenses	1,478
Other Liabilities	340
Other Net Income	2,268
Other Revenues	0
Property and Equipment	698
Research and Development	5,958
Selling, General and Administrative Expense	9,594

Output Variable	Value in 1000 USD
Assets	69,521
Liabilities	38,096
Expenses	17,030
Revenues	0
Stockholders Equity	31,425
Net Income	-14,762
Comprehensive Net Income	-14,762
BaseVar	63,458
ECR before LimitedLiability	100%
Economic Capital Ratio	230%